NCT06470633

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

To Evaluate the Efficacy and Safety of Adebrelimab Combined With Chemotherapy Neoadjuvant Therapy in Early or Local Advanced Breast Cancer After Induction Treatment of High-intensity Focused Ultrasound and Adebrelimab

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 29 (estimated)
• Sponsor: The First Affiliated Hospital with Nanjing Medical University · Academic / Other
• Sex: Female
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To explore the efficacy and safety of adebrelimab combined with chemotherapy (epirubicin + cyclophosphamide →docetaxel) neoadjuvant therapy early HR+/HER2- breast cancer with high risk factors after the induction treatment of HIFU and adebrelimab.

Conditions

• Breast Cancer
• HR+/HER2- Breast Cancer

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab 1200mg iv q3w
PROCEDURE	High Intensity Focused Ultrasoun（HIFU）	HIFU treatment at lesion site
DRUG	Cyclophosphamide	600mg/m2 iv q3w
DRUG	Epirubicin	90mg/m2 iv q3w
DRUG	Docetaxel	75mg/m2 iv q3w

Timeline

• Start date: 2024-08-01
• Primary completion: 2026-06-01
• Completion: 2026-12-31
• First posted: 2024-06-24
• Last updated: 2024-06-24